Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial

Open access
Rubin, Bernard R., Burton, Robert, Navarra, Sandra, Antigua, Joseph, Londoño, John, Pryhuber, Keith G., Lund, Margaret, Chen, Erluo, Najarian, Daryl K., Petruschke, Richard A., Ozturk, Zafer E., Geba, Gregory P.·2004·Arthritis & Rheumatism

Abstract

Objective: To evaluate the efficacy and safety of etoricoxib and indomethacin in the treatment of patients with acute gout. Methods: A randomized, double‐blind, active‐comparator study was conducted at 42 sites. A total of 189 men and women (≥18 years of age) who were experiencing an acute attack (≤48 hours) of clinically diagnosed gout were treated for 8 days with etoricoxib, 120 mg/day (n = 103), or indomethacin, 50 mg 3 times a day (n = 86). The primary efficacy end point was the patient's assessment of pain in the study joint (0–4‐point Likert scale) over days 2–5. Safety was assessed by adverse experiences (AEs) occurring during the trial. Results: Etoricoxib demonstrated clinical efficacy comparable to that of indomethacin in terms of the patient's assessment of pain in the study joint. The difference in the mean change from baseline over days 2–5 was –0.08 (95% confidence interval –0.29, 0.13) (P = 0.46), which fell within the prespecified comparability bounds of –0.5 to 0.5. Secondary end points over the 8‐day study, including the onset of efficacy, reduction in signs of inflammation, and patient's and investigator's global assessments of response to therapy, confirmed the comparable efficacy of the two treatments. The etoricoxib‐treated patients had a numerically lower incidence of AEs (43.7%) than did the indomethacin‐treated patients (57.0%) and a significantly lower incidence of drug‐related AEs (16.5% versus 37.2%; P < 0.05). Conclusion: Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout. Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.20007

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Rubin, B. R., Burton, R., Navarra, S., Antigua, J., Londoño, J., Pryhuber, K. G., Lund, M., Chen, E., Najarian, D. K., Petruschke, R. A., Ozturk, Z. E., & Geba, G. P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2004-02
Volume
50
Issue
2
Pages
598-606
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2071263587
Cited by
188
References
0
FWCI
8.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.